WO2002002606A3 - Immunisation contre une infection par chlamydia pneumoniae - Google Patents
Immunisation contre une infection par chlamydia pneumoniae Download PDFInfo
- Publication number
- WO2002002606A3 WO2002002606A3 PCT/IB2001/001445 IB0101445W WO0202606A3 WO 2002002606 A3 WO2002002606 A3 WO 2002002606A3 IB 0101445 W IB0101445 W IB 0101445W WO 0202606 A3 WO0202606 A3 WO 0202606A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chlamydia pneumoniae
- against chlamydia
- immunisation against
- pneumoniae
- immunisation
- Prior art date
Links
- 241001647372 Chlamydia pneumoniae Species 0.000 title abstract 3
- 238000002649 immunization Methods 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60139690T DE60139690D1 (de) | 2000-07-03 | 2001-07-03 | Immunisierung gegen chlamydia pneumoniae |
AT01954278T ATE440861T1 (de) | 2000-07-03 | 2001-07-03 | Immunisierung gegen chlamydia pneumoniae |
EP01954278A EP1297005B1 (fr) | 2000-07-03 | 2001-07-03 | Immunisation contre une infection par chlamydia pneumoniae |
JP2002507858A JP2004502415A (ja) | 2000-07-03 | 2001-07-03 | Chlamydiapneumoniaeに対する免疫化 |
US10/312,273 US20040005667A1 (en) | 2000-07-03 | 2001-07-03 | Immunisation against chlamydia pneumoniae |
AU2001276619A AU2001276619A1 (en) | 2000-07-03 | 2001-07-03 | Immunisation against chlamydia pneumoniae |
CA002414884A CA2414884A1 (fr) | 2000-07-03 | 2001-07-03 | Immunisation contre une infection par chlamydia pneumoniae |
US11/414,403 US20070116726A1 (en) | 2000-07-03 | 2006-05-01 | Immunisation against Chlamydia pneumoniae |
US12/543,535 US20100056447A1 (en) | 2000-07-03 | 2009-08-19 | Immunization against chlamydia pneumoniae |
US13/345,972 US20120171236A1 (en) | 2000-07-03 | 2012-01-09 | Immunization against chlamydia pneumoniae |
Applications Claiming Priority (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0016363A GB0016363D0 (en) | 2000-07-03 | 2000-07-03 | Immunisation against chlamydia pneumoniae |
GB0016363.4 | 2000-07-03 | ||
GB0017047.2 | 2000-07-11 | ||
GB0017047A GB0017047D0 (en) | 2000-07-11 | 2000-07-11 | Immunisation against chlamydia pneumoniae |
GB0017983.8 | 2000-07-21 | ||
GB0017983A GB0017983D0 (en) | 2000-07-21 | 2000-07-21 | Immunisation against chlamydia pneumoniae |
GB0019368.0 | 2000-08-07 | ||
GB0019368A GB0019368D0 (en) | 2000-08-07 | 2000-08-07 | Immunisation against chlamydia pneumoniae |
GB0020440.4 | 2000-08-18 | ||
GB0020440A GB0020440D0 (en) | 2000-08-18 | 2000-08-18 | Immunisation against chlamydia pneumoniae |
GB0022583.9 | 2000-09-14 | ||
GB0022583A GB0022583D0 (en) | 2000-09-14 | 2000-09-14 | Immunisation against chlamydia pneumoniae |
GB0027549A GB0027549D0 (en) | 2000-11-10 | 2000-11-10 | Immunisation against chlamydia pneumoniae |
GB0027549.5 | 2000-11-10 | ||
GB0031706.5 | 2000-12-22 | ||
GB0031706A GB0031706D0 (en) | 2000-12-22 | 2000-12-22 | Immunisation against chlamydia pneumoniae |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/414,403 Continuation US20070116726A1 (en) | 2000-07-03 | 2006-05-01 | Immunisation against Chlamydia pneumoniae |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002002606A2 WO2002002606A2 (fr) | 2002-01-10 |
WO2002002606A3 true WO2002002606A3 (fr) | 2002-06-06 |
Family
ID=27571146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2001/001445 WO2002002606A2 (fr) | 2000-07-03 | 2001-07-03 | Immunisation contre une infection par chlamydia pneumoniae |
Country Status (8)
Country | Link |
---|---|
US (4) | US20040005667A1 (fr) |
EP (2) | EP2166019A3 (fr) |
JP (2) | JP2004502415A (fr) |
AT (1) | ATE440861T1 (fr) |
AU (1) | AU2001276619A1 (fr) |
CA (1) | CA2414884A1 (fr) |
DE (1) | DE60139690D1 (fr) |
WO (1) | WO2002002606A2 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11845925B2 (en) | 2010-07-06 | 2023-12-19 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of RNA |
US11850305B2 (en) | 2010-07-06 | 2023-12-26 | Glaxosmithkline Biologicals Sa | Method of making lipid formulations with RNA encoding immunogens |
Families Citing this family (145)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7141244B1 (en) * | 1992-03-02 | 2006-11-28 | Chiron Srl | Helicobacter pylori proteins useful for vaccines and diagnostics |
CA2194237A1 (fr) * | 1994-07-01 | 1996-01-18 | Dermot Kelleher | Preparation a base de proteine antigene d'helicobacter pylori et dosage immunologique |
DK0909323T3 (da) * | 1996-01-04 | 2007-05-21 | Novartis Vaccines & Diagnostic | Helicobacter pylori-bakterioferritin |
CA2340283A1 (fr) | 1998-08-20 | 2000-03-02 | Aventis Pasteur Limited | Molecules d'acide nucleique codant la proteine pomp91a de chlamydia |
EP1105490A1 (fr) | 1998-08-20 | 2001-06-13 | Aventis Pasteur Limited | Molecules d'acide nucleique codant la proteine membrane d'inclusion c de chlamydia |
US6686339B1 (en) | 1998-08-20 | 2004-02-03 | Aventis Pasteur Limited | Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia |
US6649370B1 (en) | 1998-10-28 | 2003-11-18 | Aventis Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
US6607730B1 (en) | 1998-11-02 | 2003-08-19 | Aventis Pasteur Limited/Aventis Pasteur Limitee | Chlamydia antigens and corresponding DNA fragments and uses thereof |
CA2353107A1 (fr) | 1998-12-01 | 2000-06-08 | Andrew D. Murdin | Antigenes de chlamydia et fragments d'adn correspondants et leur utilisation |
MXPA01005813A (es) | 1998-12-08 | 2002-05-06 | Corixa Corp | Compuestos y metodos para tratamiento y diagnostico de infeccion por clamidia. |
US20020061848A1 (en) | 2000-07-20 | 2002-05-23 | Ajay Bhatia | Compounds and methods for treatment and diagnosis of chlamydial infection |
GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
US7297341B1 (en) | 1998-12-23 | 2007-11-20 | Sanofi Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
US6808713B1 (en) | 1998-12-28 | 2004-10-26 | Aventis Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
NZ512448A (en) | 1998-12-28 | 2004-01-30 | Aventis Pasteur | Chlamydia antigens and corresponding DNA fragments and uses thereof |
GB9902555D0 (en) | 1999-02-05 | 1999-03-24 | Neutec Pharma Plc | Medicament |
MXPA01009256A (es) | 1999-03-12 | 2003-07-14 | Aventis Pasteur | Antigenos de chlamydia y fragmentos de acido desoxirribonucleico correspondientes y usos de los mismos. |
WO2000066739A2 (fr) | 1999-05-03 | 2000-11-09 | Aventis Pasteur Limited | Antigenes de chlamydia, fragments d'adn correspondants et utilisation de ceux-ci |
EP1220925B8 (fr) | 1999-09-20 | 2008-04-23 | Sanofi Pasteur Limited | Antigenes de chlamydia , fragments d'adn correspondants et utilisations |
US6632663B1 (en) | 1999-09-22 | 2003-10-14 | Aventis Pasteur Limited | DNA immunization against chlamydia infection |
ATE463575T1 (de) | 1999-12-22 | 2010-04-15 | Aventis Pasteur | Chlamydia antigene, entsprechende dns fragmente und ihre verwendungen |
EP2270031A3 (fr) | 2000-02-28 | 2011-02-16 | Novartis Vaccines and Diagnostics S.r.l. | Expression hétérologue de protéines de Neisserial |
US20020132994A1 (en) * | 2000-04-04 | 2002-09-19 | Murdin Andrew D. | Chlamydia antigens and corresponding DNA fragments and uses thereof |
US20020071831A1 (en) * | 2000-04-04 | 2002-06-13 | Murdin Andrew D. | Chlamydia antigens and corresponding DNA fragments and uses thereof |
ATE389020T1 (de) | 2000-04-21 | 2008-03-15 | Corixa Corp | Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen |
ATE348892T1 (de) | 2000-05-08 | 2007-01-15 | Sanofi Pasteur Ltd | Chlamydia antigene, entsprechende dns fragmente und ihre verwendungen |
DE60139690D1 (de) | 2000-07-03 | 2009-10-08 | Novartis Vaccines & Diagnostic | Immunisierung gegen chlamydia pneumoniae |
GB0024200D0 (en) * | 2000-10-03 | 2000-11-15 | Smithkline Beecham Sa | Component vaccine |
US20030059896A1 (en) * | 2000-12-21 | 2003-03-27 | Shire Biochem Inc. | Novel chlamydia antigens and corresponding DNA fragments |
US7082569B2 (en) | 2001-01-17 | 2006-07-25 | Outlooksoft Corporation | Systems and methods providing dynamic spreadsheet functionality |
GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
EP1832603B1 (fr) * | 2001-06-05 | 2010-02-03 | CureVac GmbH | ARNm avec un contenu G/C augmenté, codant pour un antigène bactérien et son utilisation |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
US20050175629A1 (en) * | 2001-08-31 | 2005-08-11 | Giuseppe Del Giudice | Helicobacter pylori vaccination |
ES2386386T3 (es) | 2001-12-12 | 2012-08-20 | Novartis Vaccines And Diagnostics S.R.L. | Inmunización contra Chlamydia trachomatis |
DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
WO2003059381A2 (fr) * | 2002-01-18 | 2003-07-24 | Curevac Gmbh | Préparations immunogènes et vaccins à base d'arn |
GB0203403D0 (en) | 2002-02-13 | 2002-04-03 | Chiron Spa | Chlamydia cytotoxic-T cell epitopes |
GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
PT2395073T (pt) | 2002-11-01 | 2017-11-24 | Glaxosmithkline Biologicals Sa | Processo de secagem |
CA2506318C (fr) | 2002-11-15 | 2011-07-12 | Chiron Srl | Proteines de surface inattendues sur le meningocoque |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
ES2423800T3 (es) | 2003-03-28 | 2013-09-24 | Novartis Vaccines And Diagnostics, Inc. | Uso de compuestos orgánicos para la inmunopotenciación |
GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
PL1631264T5 (pl) | 2003-06-02 | 2018-09-28 | Glaxosmithkline Biologicals Sa | Kompozycje immunogenne oparte na biodegradowalnych mikrocząstkach zawierających toksoid błonicy i tężca |
OA13240A (en) * | 2003-08-19 | 2007-01-31 | Shell Int Research | Drilling system and method. |
CA2546836A1 (fr) * | 2003-11-21 | 2005-06-02 | Sanofi Pasteur Limited | Immunisation contre une infection par chlamydia |
BRPI0508365A (pt) * | 2004-03-02 | 2007-07-24 | Chiron Corp | composições imunogênicas para chlamydia pneumoniae |
CA2571710A1 (fr) | 2004-06-24 | 2006-11-02 | Nicholas Valiante | Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence |
EP2612679A1 (fr) | 2004-07-29 | 2013-07-10 | Novartis Vaccines and Diagnostics, Inc. | Compositions immunogènes pour une bactérie à gram positif telle que streptococcus agalactiae |
DE102004042546A1 (de) * | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
GB0502096D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Purification of streptococcal capsular polysaccharide |
GB0502095D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
CA2601924A1 (fr) | 2005-02-18 | 2006-08-24 | Novartis Vaccines And Diagnostics, Inc. | Proteines et acides nucleiques provenant de escherichia coli associe a la meningite/septicemie |
WO2006091517A2 (fr) | 2005-02-18 | 2006-08-31 | Novartis Vaccines And Diagnostics Inc. | Immunogenes d'escherichia coli uropathogene |
WO2007047749A1 (fr) | 2005-10-18 | 2007-04-26 | Novartis Vaccines And Diagnostics Inc. | Immunisations mucosiques et systemiques avec particules de replicon d’alphavirus |
CA2630220C (fr) | 2005-11-22 | 2020-10-13 | Doris Coit | Antigenes de norovirus et de sapovirus |
AU2007281934B2 (en) | 2006-01-18 | 2012-11-15 | University Of Chicago | Compositions and methods related to Staphylococcal bacterium proteins |
ES2376492T3 (es) | 2006-03-23 | 2012-03-14 | Novartis Ag | Compuestos de imidazoquinoxalina como inmunomoduladores. |
US20070259445A1 (en) * | 2006-05-05 | 2007-11-08 | Blas Cerda | Quantitative analysis of surface-derived samples using mass spectrometry |
JP2010500399A (ja) | 2006-08-16 | 2010-01-07 | ノバルティス アーゲー | 尿路病原性大腸菌由来の免疫原 |
GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
CA2699513C (fr) | 2007-09-12 | 2018-03-13 | Novartis Ag | Antigenes mutants gas57 et anticorps gas57 |
CN104292312A (zh) | 2007-12-21 | 2015-01-21 | 诺华股份有限公司 | 链球菌溶血素o的突变形式 |
US8466167B2 (en) | 2008-03-03 | 2013-06-18 | Irm Llc | Compounds and compositions as TLR activity modulators |
EP2331127A2 (fr) | 2008-09-18 | 2011-06-15 | Novartis AG | Combinaisons d adjuvant de vaccin |
HUE029265T2 (en) | 2008-10-27 | 2017-02-28 | Glaxosmithkline Biologicals Sa | Method of purifying carbohydrates from the group streptococci |
WO2010078556A1 (fr) | 2009-01-05 | 2010-07-08 | Epitogenesis Inc. | Compositions adjuvantes et méthodes d'utilisation |
WO2010079464A1 (fr) | 2009-01-12 | 2010-07-15 | Novartis Ag | Antigènes à domaines cna_b dans des vaccins contre des bactéries à gram positif |
CN102438650A (zh) | 2009-03-06 | 2012-05-02 | 诺华有限公司 | 衣原体抗原 |
ITMI20090946A1 (it) | 2009-05-28 | 2010-11-29 | Novartis Ag | Espressione di proteine ricombinanti |
EP2440245B1 (fr) | 2009-06-10 | 2017-12-06 | GlaxoSmithKline Biologicals SA | Vaccins contenant benzonaphtyridines |
WO2011008400A2 (fr) | 2009-06-16 | 2011-01-20 | Novartis Ag | Dosages haut débit de bactéricides opsoniques et dépendant d'anticorps à médiation par le complément |
EP2470205A1 (fr) | 2009-08-27 | 2012-07-04 | Novartis AG | Adjuvant contenant de l'aluminium, un oligonucléotide et une polycation |
ES2443952T3 (es) | 2009-09-02 | 2014-02-21 | Novartis Ag | Composiciones inmunógenas que incluyen moduladores de la actividad de TLR |
JO3257B1 (ar) | 2009-09-02 | 2018-09-16 | Novartis Ag | مركبات وتركيبات كمعدلات لفاعلية tlr |
MX338753B (es) | 2009-09-30 | 2016-04-29 | Novartis Ag | Conjugacion de polisacaridos capsulares de tipo 5 y de tipo 8 de staphylococcus aureus. |
EP3199177A1 (fr) | 2009-10-30 | 2017-08-02 | GlaxoSmithKline Biologicals S.A. | Purification de saccharides capsulaires de staphylococcus aureus de type 5 et de type 8 |
WO2011057148A1 (fr) | 2009-11-05 | 2011-05-12 | Irm Llc | Composés et compositions permettant de moduler l'activité des tlr-7 |
ES2631977T3 (es) | 2009-12-15 | 2017-09-07 | Glaxosmithkline Biologicals Sa | Suspensión homogénea de compuestos inmunopotenciadores y usos de la misma |
EA023725B1 (ru) | 2010-03-23 | 2016-07-29 | Новартис Аг | Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний |
AU2011243039B2 (en) * | 2010-04-16 | 2015-01-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Real time PCR assay for detection of bacterial respiratory pathogens |
EP2575988A1 (fr) | 2010-05-28 | 2013-04-10 | Tetris Online, Inc. | Infrastructure de jeu informatique asynchrone hybride interactif |
US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
ES2934240T3 (es) | 2010-07-06 | 2023-02-20 | Glaxosmithkline Biologicals Sa | Partículas de administración de tipo virión para moléculas de ARN autorreplicantes |
PL3243526T3 (pl) | 2010-07-06 | 2020-05-18 | Glaxosmithkline Biologicals S.A. | Dostarczanie rna w celu wyzwolenia wielu szlaków immunologicznych |
EP3578205A1 (fr) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | Compositions pharmaceutiques a base d'acides nucléiques modifiés et leur utilisation medicale |
JP5908477B2 (ja) | 2010-08-31 | 2016-04-26 | ノバルティス アーゲー | タンパク質をコードするrnaのリポソームによる送達に適した脂質 |
RS63949B1 (sr) | 2010-08-31 | 2023-02-28 | Glaxosmithkline Biologicals Sa | Pegilovani lipozomi za isporuku rnk koja kodira imunogen |
NZ608362A (en) | 2010-09-01 | 2015-11-27 | Novartis Ag | Adsorption of immunopotentiators to insoluble metal salts |
GB201101665D0 (en) | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
SG190679A1 (en) | 2010-10-01 | 2013-07-31 | Jason Schrum | Engineered nucleic acids and methods of use thereof |
TR201903651T4 (tr) | 2010-10-11 | 2019-04-22 | Glaxosmithkline Biologicals Sa | Antijen uygulama platformları. |
WO2012082914A1 (fr) | 2010-12-14 | 2012-06-21 | Novartis Ag | Analyse de cytométrie en flux de matériau adsorbé à des sels métalliques |
CA2860331A1 (fr) | 2010-12-24 | 2012-06-28 | Novartis Ag | Composes |
EP2667852B1 (fr) | 2011-01-27 | 2016-11-09 | GlaxoSmithKline Biologicals SA | Nanoémulsions d'adjuvant à inhibiteurs de cristallisation |
AU2012222883A1 (en) | 2011-03-02 | 2013-10-17 | Novartis Ag | Combination vaccines with lower doses of antigen and/or adjuvant |
WO2012129483A1 (fr) | 2011-03-24 | 2012-09-27 | Novartis Ag | Nanoémulsions adjuvantes avec des phospholipides |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
CA2836468C (fr) | 2011-05-17 | 2021-05-04 | The Rockefeller University | Anticorps neutralisant le virus de l'immunodeficience humaine et methodes pour les utiliser |
US10561720B2 (en) * | 2011-06-24 | 2020-02-18 | EpitoGenesis, Inc. | Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators |
JP2014520806A (ja) | 2011-07-06 | 2014-08-25 | ノバルティス アーゲー | Rna分子の送達のための有用なn:p比を有するリポソーム |
EP3332802A1 (fr) | 2011-07-06 | 2018-06-13 | GlaxoSmithKline Biologicals SA | Compositions de combinaisons immunogènes et utilisations de celles-ci |
LT2750707T (lt) | 2011-08-31 | 2019-01-10 | Glaxosmithkline Biologicals Sa | Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
CN103917245B (zh) | 2011-09-14 | 2017-06-06 | 葛兰素史密丝克莱恩生物有限公司 | 用于制备糖‑蛋白质糖缀合物的方法 |
SG11201401196WA (en) | 2011-10-03 | 2014-05-29 | Moderna Therapeutics Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
MX354924B (es) | 2011-11-07 | 2018-03-22 | Novartis Ag | Molecula portadora que comprende un antigeno spr0096 y un spr2021. |
AU2012352180A1 (en) | 2011-12-16 | 2014-07-31 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
JP2015510872A (ja) | 2012-03-07 | 2015-04-13 | ノバルティス アーゲー | Streptococcuspneumoniae抗原の増強された製剤 |
MX346678B (es) | 2012-03-07 | 2017-03-29 | Novartis Ag | Sales de arginina utiles inmunologicamente. |
RU2014140521A (ru) | 2012-03-08 | 2016-04-27 | Новартис Аг | Адъювантные составы бустерных вакцин |
US9192651B2 (en) | 2012-04-02 | 2015-11-24 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
AU2013265336A1 (en) | 2012-05-22 | 2014-12-04 | Novartis Ag | Meningococcus serogroup X conjugate |
WO2014044728A1 (fr) | 2012-09-18 | 2014-03-27 | Novartis Ag | Vésicules de membrane externe |
US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
WO2014118305A1 (fr) | 2013-02-01 | 2014-08-07 | Novartis Ag | Administration intradermique de compositions immunologiques comprenant des agonistes des récepteurs de type toll |
US10124065B2 (en) | 2013-03-08 | 2018-11-13 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
EP3052106A4 (fr) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucléotides codant des polypeptides de modulation immunitaire |
MX2016004249A (es) | 2013-10-03 | 2016-11-08 | Moderna Therapeutics Inc | Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad. |
WO2015062738A1 (fr) | 2013-11-01 | 2015-05-07 | Curevac Gmbh | Arn modifié à propriétés immunostimulantes réduites |
US10059655B2 (en) | 2013-12-19 | 2018-08-28 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
EP3083579B1 (fr) | 2013-12-19 | 2022-01-26 | Novartis AG | Lipides et compositions lipidiques destinés à la libération d'agents actifs |
WO2016010840A1 (fr) | 2014-07-16 | 2016-01-21 | Novartis Ag | Procédé d'encapsulation d'un acide nucléique dans une nanoparticule lipidique hôte |
CN107072946B (zh) | 2014-09-05 | 2022-01-11 | 诺华股份有限公司 | 用于递送活性剂的脂质和脂质组合物 |
EP3061826A1 (fr) | 2015-02-27 | 2016-08-31 | Novartis AG | Réplicons du flavivirus |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
ES2937963T3 (es) | 2015-07-21 | 2023-04-03 | Modernatx Inc | Vacunas de enfermedad infecciosa |
EP3364950A4 (fr) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | Vaccins contre des maladies tropicales |
EP3373961A4 (fr) * | 2015-11-10 | 2019-07-31 | Ohio State Innovation Foundation | Méthodes et compositions associées à une affinité humorale accélérée |
EP3439704A1 (fr) | 2016-04-05 | 2019-02-13 | GSK Vaccines S.r.l. | Compositions immunogènes |
EP3681514A4 (fr) | 2017-09-14 | 2021-07-14 | ModernaTX, Inc. | Vaccins à arn contre le virus zika |
KR20200123436A (ko) | 2018-02-12 | 2020-10-29 | 이니뮨 코퍼레이션 | 톨-유사 수용체 리간드 |
IL302448A (en) | 2020-11-04 | 2023-06-01 | Eligo Bioscience | Phage-derived particles for in situ delivery of DNA cargo into the C. acnes population |
EP4387596A1 (fr) | 2021-08-16 | 2024-06-26 | GlaxoSmithKline Biologicals SA | Vaccins à base d'arn lyophilisés à faible dose et leurs procédés de préparation et d'utilisation |
WO2023021427A1 (fr) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Lyophilisation de nanoparticules lipidiques (lnp) encapsulant de l'arn et leurs formulations |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5869608A (en) * | 1989-03-17 | 1999-02-09 | The United States Of America As Represented By The Department Of Health And Human Services | Nucleotide and amino acid sequences of the four variable domains of the major outer membrane proteins of Chlamydia trachomatis |
WO2000034483A2 (fr) * | 1998-12-08 | 2000-06-15 | Corixa Corporation | Composes et procedes pour le traitement et le diagnostic d'infections par le chlamydia |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2264810T3 (es) * | 1997-06-23 | 2007-01-16 | Loke Diagnostics Aps | Proteinas de chlamydia pneumoniae expuestas en la superficie. |
EP1032674B1 (fr) | 1997-11-21 | 2007-01-24 | Serono Genetics Institute S.A. | Sequence genomique et polypeptides de (chlamydia pneumoniae), leurs fragments et leurs utilisations, en particulier pour le diagnostic, la prevention ou le traitement d'une infection |
PT1032674E (pt) * | 1997-11-21 | 2007-03-30 | Serono Genetics Inst Sa | Sequência genómica e polipéptidos (de chlamydia pneumoniae), seus fragmentos e suas utilizações, em particular para o diagnóstico, prevenção e tratamento de infacção |
EP2218730A1 (fr) | 1997-11-28 | 2010-08-18 | Merck Serono Biodevelopment | Séquence génomique de Chlamydia pneumoniae, polypeptides, fragments et leurs utilisations, en particulier pour le diagnostic, la prévention et le traitement de l'infection |
US6248329B1 (en) * | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
US6822071B1 (en) * | 1998-11-12 | 2004-11-23 | The Regents Of The University Of California | Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease |
EP1133572A4 (fr) * | 1998-11-12 | 2005-06-15 | Univ California | Sequence genomique de chlamydia pneumoniae |
US6565856B1 (en) | 1998-12-08 | 2003-05-20 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
US20020061848A1 (en) | 2000-07-20 | 2002-05-23 | Ajay Bhatia | Compounds and methods for treatment and diagnosis of chlamydial infection |
GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
GB9902555D0 (en) | 1999-02-05 | 1999-03-24 | Neutec Pharma Plc | Medicament |
WO2000066739A2 (fr) | 1999-05-03 | 2000-11-09 | Aventis Pasteur Limited | Antigenes de chlamydia, fragments d'adn correspondants et utilisation de ceux-ci |
EP1220925B8 (fr) | 1999-09-20 | 2008-04-23 | Sanofi Pasteur Limited | Antigenes de chlamydia , fragments d'adn correspondants et utilisations |
US6632663B1 (en) | 1999-09-22 | 2003-10-14 | Aventis Pasteur Limited | DNA immunization against chlamydia infection |
ATE463575T1 (de) | 1999-12-22 | 2010-04-15 | Aventis Pasteur | Chlamydia antigene, entsprechende dns fragmente und ihre verwendungen |
US20020132994A1 (en) * | 2000-04-04 | 2002-09-19 | Murdin Andrew D. | Chlamydia antigens and corresponding DNA fragments and uses thereof |
ATE389020T1 (de) | 2000-04-21 | 2008-03-15 | Corixa Corp | Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen |
ATE348892T1 (de) | 2000-05-08 | 2007-01-15 | Sanofi Pasteur Ltd | Chlamydia antigene, entsprechende dns fragmente und ihre verwendungen |
DE60139690D1 (de) | 2000-07-03 | 2009-10-08 | Novartis Vaccines & Diagnostic | Immunisierung gegen chlamydia pneumoniae |
-
2001
- 2001-07-03 DE DE60139690T patent/DE60139690D1/de not_active Expired - Lifetime
- 2001-07-03 AU AU2001276619A patent/AU2001276619A1/en not_active Abandoned
- 2001-07-03 CA CA002414884A patent/CA2414884A1/fr not_active Abandoned
- 2001-07-03 EP EP09075245A patent/EP2166019A3/fr not_active Withdrawn
- 2001-07-03 WO PCT/IB2001/001445 patent/WO2002002606A2/fr active Application Filing
- 2001-07-03 JP JP2002507858A patent/JP2004502415A/ja active Pending
- 2001-07-03 US US10/312,273 patent/US20040005667A1/en not_active Abandoned
- 2001-07-03 EP EP01954278A patent/EP1297005B1/fr not_active Expired - Lifetime
- 2001-07-03 AT AT01954278T patent/ATE440861T1/de not_active IP Right Cessation
-
2006
- 2006-05-01 US US11/414,403 patent/US20070116726A1/en not_active Abandoned
-
2009
- 2009-08-19 US US12/543,535 patent/US20100056447A1/en not_active Abandoned
-
2012
- 2012-01-09 US US13/345,972 patent/US20120171236A1/en not_active Abandoned
- 2012-05-09 JP JP2012107538A patent/JP2012147798A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5869608A (en) * | 1989-03-17 | 1999-02-09 | The United States Of America As Represented By The Department Of Health And Human Services | Nucleotide and amino acid sequences of the four variable domains of the major outer membrane proteins of Chlamydia trachomatis |
WO2000034483A2 (fr) * | 1998-12-08 | 2000-06-15 | Corixa Corporation | Composes et procedes pour le traitement et le diagnostic d'infections par le chlamydia |
Non-Patent Citations (2)
Title |
---|
DATABASE EMBL [online] 15 March 1999 (1999-03-15), KALMAN S. ET AL.: "Chlamydia pneumoniae section 5 of 103 of the complete genome", XP002185615, accession no. AE001589 * |
KALMAN S. ET AL.: "Comparative genomes of Chlamydia pneumoniae and C. trachomatis", NATURE GENETICS, vol. 21, no. 4, 1999, pages 385 - 389, XP000853883, DOI: doi:10.1038/7716 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11845925B2 (en) | 2010-07-06 | 2023-12-19 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of RNA |
US11850305B2 (en) | 2010-07-06 | 2023-12-26 | Glaxosmithkline Biologicals Sa | Method of making lipid formulations with RNA encoding immunogens |
US11851660B2 (en) | 2010-07-06 | 2023-12-26 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of RNA |
Also Published As
Publication number | Publication date |
---|---|
CA2414884A1 (fr) | 2002-01-10 |
WO2002002606A2 (fr) | 2002-01-10 |
US20100056447A1 (en) | 2010-03-04 |
JP2004502415A (ja) | 2004-01-29 |
US20120171236A1 (en) | 2012-07-05 |
JP2012147798A (ja) | 2012-08-09 |
US20040005667A1 (en) | 2004-01-08 |
EP2166019A2 (fr) | 2010-03-24 |
US20070116726A1 (en) | 2007-05-24 |
AU2001276619A1 (en) | 2002-01-14 |
ATE440861T1 (de) | 2009-09-15 |
DE60139690D1 (de) | 2009-10-08 |
EP2166019A3 (fr) | 2010-06-09 |
EP1297005A2 (fr) | 2003-04-02 |
EP1297005B1 (fr) | 2009-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002002606A3 (fr) | Immunisation contre une infection par chlamydia pneumoniae | |
EP2168596A3 (fr) | Immunisation contre la chlamydia trachomatis | |
WO1999057280A3 (fr) | Compositions et antigenes a base de meningocoque | |
CA2361987A1 (fr) | Proteine de liaison a l'antigene du syndrome de goodpasture | |
WO2001092468A3 (fr) | Nouvelles compositions pour l'expression du transporteur 1 d'histidine de peptide humain et leurs procedes d'utilisation | |
AU2001292326A1 (en) | Nucleic acid of novel human kinesin-associated gene, protein encoded by the nucleic acid, peptide fragment thereof and anticancer agents comprising the nucleic acid and the like | |
WO2004003009A3 (fr) | Proteines immunogenes et adn les codant | |
WO2002034901A8 (fr) | Proteine kinase | |
AU2769101A (en) | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses | |
WO2002000829A3 (fr) | Nouveau polypeptide, proteine humaine 16.83 ftsh, et polynucleotide codant ce polypeptide | |
AU2002308275A1 (en) | Protein having multiple antigen/epitope sequences and being immobilized for the diagnosis of hiv infections | |
AU2002360062A1 (en) | Tumour peptide antigen derived from the human cd19 protein | |
AU2002221909A1 (en) | Method and kit for the direct identification of nucleotide sequences, amino acid sequences or antigens | |
WO2003070770A3 (fr) | Inhibiteur de protease humain de la famille kunitz genetiquement modifie | |
IL159202A0 (en) | Peptides for chlamydophila pneumoniae vaccine and diagnosis | |
WO2002046380A3 (fr) | Proteine kinase | |
WO1997039020A3 (fr) | Sequences antigeniques d'une proteine seminale et methodes immunocontraceptives | |
AU2001245693A1 (en) | Human paris-1 antigen and nucleic acids: diagnostic and therapeutic uses | |
WO2000046242A3 (fr) | PROTEINE DE 19 KILODALTONS PRODUITE PAR LA BACTERIE $i(HELICOBACTER PYLORI) | |
WO2001073037A3 (fr) | Protéine r5, nouvel antigène de protection de la surface de la cellule des streptocoques du groupe b | |
GB0002558D0 (en) | Virulence gene and protein and their use | |
GB0002555D0 (en) | Virulence gene and protein and their use | |
GB0002556D0 (en) | Virulence gene and protein and their use | |
GB0002557D0 (en) | Virulence gene and protein and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2002 507858 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2414884 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001954278 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001954278 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10312273 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |